NCT02905331 - Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

February 6, 2018

Study Completion Date

February 6, 2018

Conditions

Psoriasis

Interventions

DRUG

Guselkumab

Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.

DRUG

Placebo

Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.

Trial Locations (14)

15213

University of Pittsburgh Department of Dermatology, Pittsburgh

23502

Virginia Clinical Research, Norfolk

34470

Renstar Medical Research, Ocala

40241

Dermatology Specialists, Louisville

46168

Indiana Clinical Trial Center, Plainfield

48059

Hamzavi Dermatology, Fort Gratiot

60008

Arlington Dermatology, Rolling Meadows

02919

Clinical Partners, Johnston

V3R 6A7

Dr. Chih ho Hong Medical, Surrey

L8N 1Y2

Dermatrials Research, Hamilton

L4Y 4C5

DermEdge Research, Mississauga

15 351

Niepubliczny Zaklad Opieki Zdrowotnej Osteo-Medic s.c. Artur Racewicz i Jerzy Supronik, Bialystok

85 094

Szpital Uniwersytecki nr 1 im Dr A Jurasza, Bydgoszcz

51-685

Wromedica Irena Bielicka, Janusz Szczepanik S.C., Wroclaw

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY